Project Grant R21DA058746
Award Date
9/15/24
Completion Date
8/31/26
Dollars Obligated
$240K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Minneapolis, MN 55455, USA
Similar Awards
This $265,302 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to investigate the neural mechanisms underlying opioid use disorder (OUD) and relapse risk during abstinence. The funded project will map the functional and anatomical pathways between the anterior and posterior paraventricular nucleus of the thalamus (PVT) and the nucleus accumbens (NAc), which have been implicated in the...
The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), awarded a $267,310 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the Regents of the University of Minnesota. The award will fund research to investigate the role of the neuropeptide VGF and its derived peptide TLQP-62 in facilitating synaptic plasticity in the nucleus accumbens and their contribution to opioid withdrawal behaviors. Key research activities include...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $2,134,928 to the Regents of the University of Minnesota to develop novel, brain-penetrant, small molecule biased allosteric modulators (BAMs) of the neurotensin receptor 1 (NTSR1) to attenuate relapse to opioid seeking in individuals with opioid use disorder (OUD). The research aims to validate NTSR1 as a drug target for OUD treatment...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund research to investigate the role of cholinergic interneurons in the ventral tegmental area on opioid-related behaviors. The $373,181 grant, awarded on July 15, 2024 with a completion date of June 30, 2027, aims to determine whether mu-opioid receptors on cholinergic interneurons contribute to opioid reward, consumption, and withdrawal, and how...
This $403,542 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to profile projection-specific proteome associated with the incubation of oxycodone craving. The project will focus on the orbitofrontal cortex (OFC) to dorsal striatum (DS) projections, analyzing proteome changes in OFC neuronal somas (Aim 1) and OFC-DS projection-specific synaptoneurosomes in the DS (Aim 2) during the incubation of oxycodone...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $419,876 to conduct preclinical trials targeting the neuropeptide S (NPS) receptor to mitigate opioid taking and seeking behaviors in animal models. The goals of the project are to demonstrate proof-of-concept that NPS receptor-targeted molecules can reduce oxycodone self-administration and motivation in rats, which could inform the...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $818,513.00 to investigate the role of dopamine signaling in the basolateral amygdala on individual differences in reward-learning strategies and addiction-like behaviors. The 5-year study, starting on September 15, 2024, will focus on how Pavlovian reward-learning strategies, such as sign tracking versus goal tracking, predict unique...
This Project Grant award of $847,000 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to evaluate the therapeutic potential of the neuropeptide S receptor 1 (NPSR1) as a target for reducing opioid self-administration and relapse in opioid use disorder (OUD). The research team at the University of Tennessee Health Science Center plans to leverage pharmacological tools to agonize and antagonize NPSR1 and test...
The National Institute on Drug Abuse (NIDA) awarded a $2,223,769 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of California, San Diego (UCSD) to investigate the individual and combined impact of HIV and opioids on inflammasome-mediated neuroinflammation and neurotoxicity. The 5-year study, which commenced on April 15, 2025, aims to uncover the mechanistic intersection between HIV and opioids that leads to more severe neurological...
This Project Grant award from the National Institute on Drug Abuse (NIDA), part of the NIH's Drug Use and Addiction Research Programs (CFDA 93.279), will fund a $751,043 research project at the University of Massachusetts Medical School focused on investigating the cellular and molecular mechanisms underlying the complex co-morbidity of opioid use disorder (OUD), major depressive disorder (MDD), and HIV in the human brain. The project will leverage single-cell sequencing technologies and other...